Colesterol y triglicéridos como marcadores bioquímicos del estado de la enfermedad del paciente con leucemia linfocítica aguda

Abstract

ResumenObjetivo: Determinar la relación de los niveles séricos de colesterol y triglicéridos con el estado de respuesta al tratamiento quimioterápico de inducción de pacientes con leucemia linfocítica aguda. Material y Métodos: La muestra la conforman 25 pacientes de 2 a 18 años de edad, admitidos al Instituto de Enfermedades Neoplásicas con un diagnóstico reciente de leucemia linfocítica aguda; determinándose en ellos sus concentraciones séricas de colesterol total, colesterol-HDL, colesterol-LDL y triglicéridos, antes y después de la primera fase de la quimioterapia de inducción. Resultados: Solamente 23 pacientes respondieron al tratamiento y en ellos observamos un incremento de 19,24 ± 4,49 mg/dL a 46,84 ± 15,38 mg/dL para el colesterol-HDL; y un descenso de 153,66 ± 36,39 mg/dL a 79,79 ± 34,53 mg/dL para los triglicéridos (p<0,0001). Por el contrario, en los pacientes que no respondieron al tratamiento, se obtuvo un incremento de 14,64 ± 2,46 mg/dL a 23,13 ± 14,23 mg/dL para el colesterol-HDL y un incremento de 121,88 ± 0,56 mg/dL a 161,01 ± 75,25 mg/dL para los triglicéridos. Conclusión: Las concentraciones séricas de colesterol y triglicéridos se relacionan con el estado de la enfermedad del paciente con leucemia linfocítica aguda. Proponemos a estos metabolitos, como marcadores bioquímicos en el seguimiento clínico de esta enfermedad. Palabras clave: Hipocolesterolemia; lipoproteinas del colesterol HDL; lipoproteinas del colesterol LDL; leucemia linfocítica aguda; triglicéridos.Cholesterol and triglycerides as biochemical markers of the state of the patient's illness with acute lymphocytic leukemia Abstract Objective: To determine the relationship of cholesterol and triglycerides serum levels with the response to induction chemotherapy treatment in patients with acute lymphocytic leukemia. Material and Methods: The sample consisted in 25 patients 2 through 18 years-old admitted to the Neoplasia Diseases Institute with a recent diagnosis of acute lymphocytic leukemia in whom serum concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were determine, before and after the first phase of the induction chemotherapy. Results: Only 23 patients responded to the treatment and in them we observe an increment from 19,24 ± 4,49 mg/dL to 46,84 ± 15,38 mg/dL for the HDL-cholesterol, and a descent from 153,66 ± 36,39 mg/dL to 79,79 ± 34,53 mg/dL for the triglycerides (p<0,0001). On the contrary, in the patients that didn't respond to the treatment, an increment was obtained from 14,64 ± 2,46 mg/ dL to 23,13 ± 14,23 mg/dL for HDL-cholesterol and an increment from 121,88 ± 0,56 mg/dL to 161,01 ± 75,25 mg/dL for triglycerides. Conclusion: Serum concentrations of cholesterol and triglycerides are correlated with the state of the patient's illness with acute lymphocytic leukemia. We propose these metabolites as biochemical markers in the clinical pursuit of this illness.

Untargeted metabolomic and lipidomic analyses reveal lipid dysregulation in the plasma of acute leukemia patients

“…Within the increase in glycerolipids, TG was the most relevant. Altered glycerophospholipid metabolism has previously been associated with disease progression in pediatric ALL patients (Yunnuo et al, 2014) and an increase in TG in conjunction with a decrease in CL has been reported in both AML and ALL (Nahid et al, 2013), which has been related to a poor response to treatment (Guzmán and Sandoval, 2004). Particularly, Pabst et al ( 2017) From the point of view of the evolution of the disease, it has been described in other works, that patients with myelodysplastic syndromes who progressed to AL had higher TG levels than those who did not evolve (Qiao et al, 2022) and that in patients with ALL, after a 5-year disease-free period, they developed dyslipidemia with increased plasma TG, increased LDL CL, and decreased HDL CL, which was associated with an increased risk of atherosclerotic disease (Morel et al, 2017).…”